VEGFA and wet macular degeneration: Together these molecules represent the first-line therapy for wet AMD [8], with many large-scale and well-run clinical trials demonstrating their safety and efficacy [9–11]. Recently, Brolucizumab has been developed as a new long-acting anti-VEGF agent and clinical trials are underway to define its efficacy and safety profile [12]. Clinical trial results may not, however, be replicable in real-world practice where patients frequently fall outside of the rigid inclusion or exclusion criteria used in the design of such trials and are exposed to a less intensive course of treatment.